Intravesical Infusion of Oncolytic Virus CG0070 in the Treatment of Bladder Cancer

Paola Grandi; Andrea Darilek; Anay Moscu; Anu Pradhan; Roger Li

doi:10.1007/978-1-0716-3291-8_19

Intravesical Infusion of Oncolytic Virus CG0070 in the Treatment of Bladder Cancer

Methods Mol Biol. 2023:2684:303-317. doi: 10.1007/978-1-0716-3291-8_19.

Authors

Paola Grandi¹, Andrea Darilek¹, Anay Moscu², Anu Pradhan², Roger Li^{3

4}

Affiliations

¹ CG Oncology, Inc., Irvine, CA, USA.
² Department of Pharmacy, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
³ Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Roger.Li@moffitt.org.
⁴ Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Roger.Li@moffitt.org.

PMID: 37410243
DOI: 10.1007/978-1-0716-3291-8_19

Abstract

CG0070 is a conditionally replicating oncolytic adenovirus that preferentially replicates within and kills Rb-defective cancer cells. It has been used successfully in an intravesical formulation to treat Bacillus Calmette-Guerin (BCG) unresponsive carcinoma in situ (CIS) containing non-muscle-invasive bladder cancer. As a self-replicating biologic, it shares many characteristics with intravesical BCG but has other unique features. Herein, we detail recommended standardized protocols for bladder infusion of CG0070 for the treatment of bladder cancer and provide many useful tips for trouble shooting.

Keywords: Bladder cancer; CG0070; Immunotherapy; Intravesical infusion; Oncolytic virus.

MeSH terms

Adenoviridae / genetics
Adjuvants, Immunologic
BCG Vaccine
Humans
Neoplasm Invasiveness / pathology
Oncolytic Viruses* / genetics
Urinary Bladder Neoplasms* / pathology
Urinary Bladder Neoplasms* / therapy

Substances

BCG Vaccine
Adjuvants, Immunologic